Physician profile
John Lien
NPI 1932291648
$31,757.37
in general payments reported to CMS, 2019-2025
32 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,326 · 2021: $1,643 · 2022: $6,854 · 2023: $2,535 · 2024: $1,747 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,766 · Education: $28.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,765.96 |
| Education | $28.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,177.26 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $6,520.21 | 2019-2025 | Watchman Flx |
| Biotronik INC. | $2,273.70 | 2019-2022 | |
| Lilly USA, LLC | $1,687.50 | 2019-2020 | |
| Medtronic Vascular, INC. | $1,282.86 | 2019-2020 | |
| Amarin Pharma, INC. | $1,233.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $1,093.96 | 2019-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $1,050.09 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $1,047.39 | 2019-2025 | Camzyos, Eliquis, Daklinza |
| Astrazeneca Pharmaceuticals Lp | $880.23 | 2019-2025 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $601.96 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $565.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $495.16 | 2019-2024 | Xarelto |
| Amgen INC. | $425.62 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $339.84 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $320.82 | 2019-2025 | Mitraclip |
| Inspire Medical Systems, INC. | $275.80 | 2022-2023 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $208.99 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $171.77 | 2020-2024 | Nexletol |
| Shockwave Medical, INC | $162.07 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $152.87 | 2019-2024 | |
| Medtronic, INC. | $143.11 | 2021-2022 | |
| Silk Road Medical, INC. | $126.79 | 2021 | |
| Gilead Sciences, INC. | $124.59 | 2019 | |
| Cvrx, INC. | $89.04 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.27 | 2023 | Lifevest |
| Kiniksa Pharmaceuticals, Ltd. | $52.13 | 2023 | Arcalyst |
| Akcea Therapeutics, INC. | $50.44 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $46.53 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $40.59 | 2019 | |
| Heartflow, INC. | $22.08 | 2023 | Ffrct |
| Sanofi-Aventis U.S. LLC | $16.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.